Neuroprotection

Phase 3Small molecule

TThe Central and Eastern European Gynecologic Oncology Group

Neuroprotection is one of 15 small molecule programs targeting Premature rupture of membranes. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Premature Rupture of MembranesActive, not recruiting

Premature Rupture of MembranesPhase 3

Active, not recruiting

Competition

Competitive Landscape

22 competitors in Premature Rupture of Membranes

#DrugCompanyPhaseTrials

Cytotec

Pfizer

Approved

4 2

Imdur

OOmnivium

Approved

—3

E-Mycin

AAzurity Pharmaceuticals

Phase 3

1 4

Procardia

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

1 5

Zithromax

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

1 6

Antibiotic

Pfizer

Phase 3

1 7

PGE2

UUnknown Sponsor

Approved

2 8

Indocin

LLife Extension Foundation Inc.

Phase 2

1 9

Antibiotics Administration

TThe Central and Eastern European Gynecologic Oncology Group

Phase 3

1 10

Neuroprotection

TThe Central and Eastern European Gynecologic Oncology Group

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 3Recruiting

Premature Rupture of Membranes

NCT07107477

Clinical

Trials by Indication[1]

Premature rupture of membranes1 trial

TAILORED Therapeutic Regime in Patients With Preterm Premature Rupture Of Membranes to Prolong Pregnancy, Improve Maternal and Neonatal Outcomes, and Reduce Antibiotic Burden

Recruiting·TThe Central and Eastern European Gynecologic Oncology Group·Phase 3·NCT07107477·138 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Neuroprotection. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Neuroprotection compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Neuroprotection. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The Central and Eastern European Gynecologic Oncology Group company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: TThe Central and Eastern European Gynecologic Oncology Group

Neuroprotection

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Premature rupture of membranes1 trial

References

Drug Info

Quick Facts

Related News